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Introduction  
Bioinformatics was first coined in 1970 to refer to information stored in biological systems. But in 
today’s terms it has become synonymous with the generation and interrogation of large scale 
biological data. The catalyst for this change in meaning was undoubtedly the completion of the 
Human Genome Project in the late 1990’s [1]. It is instructive to remember that the primary goal of 
bioinformatics is to increase the understanding of biological processes, making it a fundamentally 
scientific discipline. What sets it apart is the use of intensive computational techniques to achieve 
this aim.  This broad goal is perhaps one of the reasons that so many related areas are interrogated 
with a bioinformatics approach, everything from pure biological processes like genome assembly, 
protein structure analysis and RNA expression analysis, to data and text mining, to image analysis. 
Thus, it is an essential component of translational medicine. 
 
From an oncological perspective the allure of bioinformatics has been its promise to unlock the 
wealth of the increasingly complex biological data generated from cancers. Cancer is fundamentally 
a genomic disease therefore one would assume if we can analyse the cancer’s genome, its 
derivatives (RNA, proteins, metabolites ), structure (chromatin, ploidy status) and regulation 
(methylation) we should be able to leverage this information to a therapeutic advantage. Indeed the 
ultimate expression of this aspiration is ‘personalised medicine’; that every patient and their cancer 
can be broken down into its constituent parts and an individualised solution delivered.   
 
As oncology enters  ‘big data’ , the conceptual framework of the dimensional challenges of ‘big data’ 
[2] has been neatly repurposed to help one understand the scale of this challenge [3]. Specifically, 
one needs to consider: 1) Volume – the amount of data generated, 2) Variety – the differing data 
sources from which we gather, including genomics but also electronic records, imaging, digital 
pathology, 3) Velocity – the rate at which data is generated by technological advances and the need 
to analyse such data in clinically relevant timescales, 4) Value to the clinician and the patient. Key 
steps essential to all 4 ‘V’ are data collection, integration, interpretation and reproducibility, 
highlighting the central role of Bioinformatics in the ‘big data’ area.  
 
Data collection  
The quality of tissue entered into an analysis pipeline will tremendously influence the quality and 
reliability of the output data. Standard practice in all clinical pathology is to fix tissue in formalin and 
embed it in paraffin blocks (FFPE). Whilst this process has been integral to the generation of high 
quality pathology reporting, the process has lasting repercussions on the integrity of DNA [4,5] and 
RNA for multi-omic testing.  Recently, alternative protocols have been proposed, with improvement 
on the results [6]. Fresh do not suffer the same artefacts producing higher quality data but such 
samples are not collected as standard practice. Tumour mutations are typically assessed using a 
targeted panel of known driver genes, for example APC, p53 and RAS in colorectal cancer. These are 
chosen empirically based on known biological processes in any given tumour site. The advantage of 
these approaches is their accessibility, the limited amount of data produced and the ability to 
sequence regions to high depth of coverage thereby increasing confidence in the final call [7].  
However, the inherent bias of choosing the gene panel up front cannot be understated.  Next 
generation sequencing (NGS) on the other hand provides an agnostic appraisal of either the whole 
genome, the whole exome or the transcriptome [8]. This allows for assessment of novel or less 
frequent mutations that are present at an individual level as well as variations in copy number and 
gene rearrangements. The trade-off however is that the depth of coverage is usually to a much 
lower level, thereby decreasing the confidence with a mutation can be ‘called’.  Neither approach is 
infallible but it is incumbent on those attempting to understand the clinical implications of the data 
to understand these technical limitations.  The increasing availability and decreasing cost of NGS 
means that it is likely to become much more commonplace in medical applications [9,10]. Another 
important issue is that the sensitivity of a mutation call is influenced by the proportion of tumour 
contained within the clinical sample. Techniques such a microdissection will increase the yield of 
tumour but are not scalable and time consuming, and have the potential expense of understanding 
the associated stromal interactions with that tumour, overlooking valuable information on the 
tumour microenvironment.  One emerging answer to this problem could be single cell sequencing 
which has seen high profile publications regarding the cellular heterogeneity of DNA, RNA, proteins 
and metabolites [11]. It has been argued that this sudden interest is due to three factors: 
technological advances that allow whole genome/transcriptome amplification, lower cost for higher 
throughput and the invention of technology for single cell manipulation [12]. Again we see examples 
of volume and velocity.   
 
However, volume and speed do not necessarily guarantee a ‘fair’ assessment, which must relies on 
carefully planning and understanding of all potential confounders at the collection level. What type 
of tissue was analysed, on what platform and how best to integrate and analyse the information.  
 
Integration and interpretation challenges 
Being able to take a macroscopic overview of the volume of data generated, even when organised 
efficiently, is a monumental task. What complimentary methods help to provide internal validation 
and different biological information, for example immunohistochemistry to validate the loss of 
heterozygosity in copy number outputs from NGS or to confirm transcriptomic effects with protein 
stains? Orthogonal practices such as digital analysis of the biopsy or resection site can greatly help 
but equally raises questions about which modality represents ‘truth’ and how to do you reconcile 
conflicting findings. A combination of both low and high throughput technologies (variety), and by 
applying novel bioinformatic and machine learning algorithms to existing data such as imaging and 
pathology slides [13–15], will allow maximal yield ( value) from patient data.  
For the data to be clinically useful it must be interpretable, which in turn means it has to be 
presented in a synthesised, succinct, informative fashion. The tasks involved with data integration 
and interpretation are usually the last steps in the data production pipeline but they are far from 
trivial, and have the power to influence the future of medical research and practice. Many examples 
could be provided here. We consider amongst them the SHIVA trial [16], a multicentre, open-label, 
proof-of-concept, randomised, controlled phase 2 trial. The aim was to assess the efficacy of 
molecularly targeted agents, chosen on the basis of tumour molecular profiling but used outside 
their indications, in patients with advanced cancer. This trial was ultimately unsuccessful in its 
primary aim, in that the use of molecularly targeted agents in a histology agnostic way, did not 
improve progression-free survival compared with treatment at physician's choice. More importantly, 
it started a heated discussion in the clinical and research communities when published in 2015[17].  
The bioinformatic resourcing and effort to create a database to process and present all the data 
collected, within clinical trial timelines, has been be commended [3]. That the trial was unsuccessful 
demonstrates that even with excellent data collection the interpretation and use of such data is far 
from straight forward. This includes understanding the role of co-activating mutations, cross talk 
between pathways at a transcriptomic level and the disease type itself, which was specifically 
ignored in SHIVA. The best example of this is BRAF V600E which is an excellent therapeutic target in 
melanoma [18] but not so in colorectal cancer [19]. Given how important these studies are for our 
understanding of disease and the implications they have on shaping our future clinical strategies, it 
is key that these efforts are extremely carefully designed, using  input from a community of 
scientists and medical experts ranging from tumour biologists, immunologists, geneticists, 




Lack of reproducibility is a significant problem in biomedicine, and will further worsen if careful steps 
are not taken. Recently, frameworks have been developed, such as RIPOSTE [20], to encourage 
researchers to address fundamental bioinformatics and statistical issues at each stage of the 
process, right from the study design stage. Some of the requirements will be familiar to biomedical 
scientists and clinicians, however many will not be aware of the necessary quality control 
procedures for sample handling, data verification and cross validation to maximize reproducibility. 
For ‘omic’ studies, attempts must be made to control for known and unknown biases by verified 
processes of normalisation and batch effect correction. Hence, there is a real need to engage with 
bioinformaticians as early as possible in the study workflow, to ensure the correct steps are taken 
from data collection right to analysis and interpretation.  Analysis scripts and algorithms for data 
processing and presentation should be readily available in repositories for dissemination and 
replication, as necessity[21,22]   
The scale of ‘big data’ means that clinicians must also realise that there is a high potential false 
discovery rate (FDR) and adjustments must be made to account for multiple testing. Only up front 
discussions about data collection and an analysis plan can allow for minimisation of bias. The goal is 
therefore to embed this process into clinical trial design where so many ‘knowns’ are already 
accounted for. However, the velocity with which data accumulates exponentially outstrips to the 
rate at which trials get opened and completed. Therefore tissue bio-banking and data storage must 
be considered up front as much as is possible [23] with appropriate patient consent to allow for 
testing at later date.  
 
Conclusions 
Although patient journeys through health systems are linear in a temporal sense, there is a need to 
anticipate future requirements and think in a circular fashion about the processes that needs to take 
place in order to maximise the value of available data. As Figure 1 demonstrates we must constantly 
take new ideas forwards into trials but novel findings backwards to better understand what we 
already know. The clinician will be familiar with the language ‘to translate from the bench to bedside 
and back again’. Understanding and employing bioinformatics to collect, integrate and present data, 
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